Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$271000.0.

  • Phathom Pharmaceuticals' Cash from Financing Activities fell 10022.2% to -$271000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $25.9 million, marking a year-over-year decrease of 9298.79%. This contributed to the annual value of $182.8 million for FY2024, which is 5027.64% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$271000.0 for Q3 2025, which was down 10022.2% from $80000.0 recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Cash from Financing Activities high stood at $212.0 million for Q4 2023, and its period low was -$271000.0 during Q3 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' median Cash from Financing Activities value was $24.6 million (recorded in 2022), while the average stood at $52.3 million.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Cash from Financing Activities skyrocketed by 93880000.0% in 2024 and then crashed by 10022.2% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Cash from Financing Activities stood at $24.6 million in 2022, then skyrocketed by 761.9% to $212.0 million in 2023, then crashed by 87.71% to $26.0 million in 2024, then crashed by 101.04% to -$271000.0 in 2025.
  • Its last three reported values are -$271000.0 in Q3 2025, $80000.0 for Q2 2025, and $26.0 million during Q4 2024.